Revolutionizing bioreactor control
Boosting efficiency with Raman technology and the Catalyx OpenBIO® Bioreactor Controller
A pharmaceutical company integrated more than 30 Endress+Hauser Raman analyzers across multiple sites, including Pennsylvania. The analyzers, including Rxn2 and Rxn4 models, were deployed in R&D and manufacturing. Raman data was incorporated into the company’s bioreactor control platform using the Catalyx OpenBIO® Bioreactor Controller, enabling real-time adjustments to feed rates. This integration optimizes cell growth conditions, ensuring consistent biological process performance.
The results
-
Implementing the Catalyx OpenBIO® Bioreactor Controller and the Raman analyzers and probes helped improve efficiency, maximize yields and the number of batches that could be processed, translating to an ROI of approximately $300,000 per unit yearly.
The challenge
The primary challenge for the pharmaceutical company was to enhance process efficiency for technicians and scientists. Traditionally, samples were manually extracted from vessels, analyzed in a lab and then used to adjust feed rates. This manual process was time-consuming and prone to contamination, which could compromise the integrity of the samples and the accuracy of the data obtained.
The solution
The solution to these challenges for the pharmaceutical company rested in the Catalyx OpenBIO® Bioreactor Controller platform provided by Catalyx in tandem with Endress+Hauser’s Raman Rxn2 and Rxn4 analyzers and Rxn-10 probes. Using Endress+Hauser’s optical analysis measurement instruments and Catalyx’s platform, the pharmaceutical company can now read glucose concentrations from a bioreactor and use this data to make immediate adjustments, ensuring optimal conditions for cell growth.